Shares of Mylan NV (NASDAQ:MYL) have been assigned an average recommendation of “Buy” from the twenty-four analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $30.24.
MYL has been the subject of a number of recent research reports. Barclays initiated coverage on Mylan in a research note on Tuesday, June 11th. They set an “overweight” rating and a $26.00 price objective for the company. Royal Bank of Canada lowered their price objective on Mylan to $26.00 and set an “outperform” rating for the company in a research note on Wednesday, May 8th. Mizuho lifted their price objective on Mylan from $25.00 to $27.00 and gave the company a “neutral” rating in a research note on Tuesday, July 30th. Evercore ISI reiterated a “buy” rating on shares of Mylan in a research note on Friday, August 9th. Finally, TheStreet cut Mylan from a “c-” rating to a “d+” rating in a research note on Friday, August 2nd.
In related news, Director Robert J. Coury acquired 49,859 shares of the firm’s stock in a transaction on Friday, August 2nd. The shares were acquired at an average cost of $20.06 per share, for a total transaction of $1,000,171.54. Following the completion of the transaction, the director now directly owns 947,194 shares in the company, valued at approximately $19,000,711.64. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Richard A. Mark bought 4,000 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were acquired at an average cost of $20.97 per share, for a total transaction of $83,880.00. Following the purchase, the director now owns 4,000 shares of the company’s stock, valued at approximately $83,880. The disclosure for this purchase can be found here. Corporate insiders own 0.82% of the company’s stock.
MYL traded down $1.52 on Wednesday, hitting $18.20. 8,498,305 shares of the company were exchanged, compared to its average volume of 6,987,149. The stock’s fifty day moving average price is $19.13. The company has a quick ratio of 0.77, a current ratio of 1.37 and a debt-to-equity ratio of 1.15. Mylan has a 12 month low of $16.63 and a 12 month high of $39.59. The company has a market capitalization of $10.05 billion, a PE ratio of 3.97, a PEG ratio of 0.92 and a beta of 1.77.
Mylan (NASDAQ:MYL) last posted its quarterly earnings results on Monday, July 29th. The company reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.08. Mylan had a return on equity of 18.93% and a net margin of 0.30%. The business had revenue of $2.85 billion for the quarter, compared to analyst estimates of $2.82 billion. During the same period last year, the company earned $1.07 EPS. Mylan’s revenue for the quarter was up 1.5% compared to the same quarter last year. Sell-side analysts forecast that Mylan will post 4.3 earnings per share for the current year.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Featured Article: Federal Reserve
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.